Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Pharmaceutical industry

Gilead Used `Revenue-Driven Pricing' on Hep C Drug, Senators Say

Editor's pick
Bloomberg
1 December 2015
Access to healthcare

Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs

Editor's pick
Sydney Morning Herald
1 December 2015
Hepatitis C treatment

South Africa’s ‘other’ virus

Editor's pick
Health-e
1 December 2015
Hepatitis C treatment

High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy

News
30 November 2015
Hepatitis C treatment

Morocco without hepatitis C in 2020

Editor's pick
Morocco World News
27 November 2015
Hepatitis C treatment

UK: Hep C patients to get NHS access to three new therapies

Editor's pick
Pharma Times
27 November 2015
Hepatitis C treatment

Pricey HCV Drugs Worth the Cost

Editor's pick
MedPage Today
27 November 2015
Hepatitis C treatment

Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction

News
25 November 2015
Drug interactions & pharmacokinetics

Study reveals potential challenges for scaling up of HCV therapy in UK

News
24 November 2015
Hepatitis C treatment

The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine Daclatasvir

Editor's pick
Medicines Patent Pool
23 November 2015
Hepatitis C treatment

Liver fibrosis improves after successful treatment for hepatitis C

News
23 November 2015
Finance & funding

Why We Should Be Willing to Pay for Hepatitis C Treatment

Editor's pick
Huffington Post
23 November 2015
New & experimental hepatitis C treatment

Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice

News
20 November 2015
New & experimental hepatitis C treatment

Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C

News
20 November 2015
Hepatitis C treatment

Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows

News
17 November 2015
Hepatitis C treatment

Leading liver doctors: Hepatitis C patients must be treated

Editor's pick
American Association for the Study of Liver Diseases press release
17 November 2015
New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3

News
16 November 2015
Hepatitis C treatment

Pricing Pressures: How the Business of Medicine Affects the Price of Therapy

Editor's pick
Healio HCV Next
16 November 2015
Hepatitis C treatment

Medicare will spend $9 billion on Hepatitis-C drugs this year

Editor's pick
PBS NewsHour
16 November 2015
New & experimental hepatitis C treatment

Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs

News
16 November 2015
Hepatitis C treatment

People with HIV and HCV co-infection achieve high HCV cure rates with grazoprevir/elbasvir

News
15 November 2015
Hepatitis C treatment

U.S. FDA approves new indications for Harvoni®, Gilead’s once-daily single tablet regimen for chronic hepatitis C

Editor's pick
Gilled press release
13 November 2015
Access to healthcare

The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

Editor's pick
Medicines Patent Pool
9 November 2015
Hepatitis C treatment

New hepatitis C drug can slow heart rate

Editor's pick
Health24
9 November 2015